Clinical trials: Respiratory Tract Infection
Community Acquired Bacterial Pneumonia, Complicated Intra-Abdominal Infection
Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia
The main purpose of this study is to compare the safety of tigecycline versus a ceftriaxone regimen in pediatric subjects (aged 8 to 17 years) with complicated intra-abdominal infections (cIAI) and community acquired pneumonia…
- Trial name
- NCT00914888
- Testing
- Tigecycline, cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside, CAP: Ceftriaxone, plus if applicable oral clarithromycin
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
COVID-19
Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above
This is a randomized, double blind, positive controlled study to evaluate the safety and immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above who have been vaccinated with…
- Trial name
- COVID-19 (NCT05374954)
- Testing
- Omicron COVID-19 Vaccine (Vero Cell), Inactivated, COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- 10 sites in China
- Volunteers
- 4,200 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Sinusitis, Nasal Polyps
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
This study will evaluate the effect and safety of 611 in patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP).
- Conditions
- Sinusitis, Nasal Polyps, Polyps
- Trial name
- NCT05865496
- Testing
- 611
- Where
- 4 sites in China
- Volunteers
- 90 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Influenza A Subtype H5N1 Infection
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
The purpose of this study is to test the recombinant vaccine for safety and immunogenicity in healthy adults volunteers. Single dose, intranasally administered vaccine using an adenovirus-recombinant vector has provided a safe…
- Trial name
- NCT00755703
- Testing
- Pandemic Influenza Vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Upper Respiratory Tract Infection
To Compare the Efficacy and Tolerability of A. Paniculata/A. Chilensis in Individuals With URTI
Conventional therapy of upper respiratory tract infection (URTI) is not always effective and sometimes leads to side effects and also to inappropriate use of antibiotic.
- Trial name
- A Paniculata (NCT04955327)
- Testing
- A. Paniculata, A. Chilensis, A. Paniculata and A. Chilensis
- Where
- 5 sites in India
- Volunteers
- 225 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
COVID-19 Pulmonary Complications, COVID-19
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019…
- Trial name
- NCT04382586
- Testing
- Zanubrutinib, Supportive Care
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- BeiGene
Recurrent Respiratory Tract Infections
Study of Pidotimod in Children With Recurrent Respiratory Tract Infections (RRI)
The purpose of this study is to assess the efficacy of pidotimod as treatment in participants with recurrent respiratory tract infections.
- Trial name
- P-CRESCENT (NCT04322669)
- Testing
- Pidotimod
- Where
- 16 sites in China
- Volunteers
- 338 people
- Sponsor
- Almirall, S.A.
Influenza
A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to alleviation of symptoms in patients with uncomplicated influenza virus…
- Trial name
- CAPSTONE 1 (NCT02954354)
- Testing
- Baloxavir Marboxil, Oseltamivir
- Volunteers
- 1,436 people
- Sponsor
- Shionogi
TUBERCULOSIS, PULMONARY
Validating the Use of Blood Transcriptomic Signatures for the Diagnosis of Active Pulmonary Tuberculosis
ISIT-TB Prototype is a diagnostic assay based on a transcriptional blood signature suggestive of the detection of Mycobacterium tuberculosis.
- Trial name
- ISIT-TB (NCT04995406)
- Testing
- ISIT-TB prototype
- Where
- South Africa
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- BioMérieux
Bacterial Pneumonia
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of Community-Acquired Pneumonia
- Trial name
- CAP (NCT00621504)
- Testing
- Ceftaroline fosamil for Injection, IV Ceftriaxone, Clarithromycin
- Where
- 168 sites in United States, Argentina and 21 more
- Volunteers
- 606 people
- Sponsor
- Forest Laboratories
COVID-19, SARS-CoV-2 Infection
The Safety and Immunogenicity of SCTV01C in Healthy Population Aged ≥18 Years Previously Vaccinated With Inactivated COVID-19 Vaccine.
The objective of this study is to evaluate the safety, tolerability, and immunogenicity of SCTV01C in healthy population aged ≥18 years previously vaccinated with inactivated COVID-19 vaccine.
- Trial name
- NCT05043285
- Testing
- SCTV01C
- Where
- United Arab Emirates
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Covid19
Study to Evaluate Efficacy and Safety of "VIRACIDE" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)
This is a double blind randomized placebo controlled study will be conducted on 124 subjects, 50 years and older with mild or asymptomatic COVID-19.
- Trial name
- NCT04596085
- Testing
- Investigational Product - ViraCide
- Where
- 2 sites in India
- Volunteers
- 118 people
- Sponsor
- The Herb, Inc
Thrombopenia, Covid19
COVID-19 ThromboprophylaXIs Study of Novel FXIa Inhibitor Frunexian (EP-7041) in ICU Patients
This is a multicenter, open-label, single cohort study of patients with confirmed COVID-19 syndrome who based on clinical judgment require care in an intensive care unit, regardless of whether or not mechanical ventilation is in…
- Trial name
- NCT05040776
- Testing
- EP-7041 Injection
- Where
- United States
- Sponsor
- eXIthera Pharmaceuticals
Staphylococcus Aureus
Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs
Patients who are at least 7 years old with stable Cystic Fibrosis who have Staphylococcus aureus in their Lungs will be enrolled into the study and receive one dose of Aurexis® intravenously on Study Day 1, and will be followed…
- Trial name
- NCT00198289
- Testing
- Aurexis® (tefibazumab)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bristol-Myers Squibb
Bronchitis, Chronic
A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Acute Symptoms of Chronic Bronchitis
This study was performed to confirm that a single 2.0-g dose of azithromycin SR is at least as effective as 7 days of levofloxacin 500 mg/day in adults with acute exacerbation of chronic bronchitis Secondary objectives: To assess…
- Trial name
- NCT00644449
- Testing
- azithromycin SR (Zithromax; compound: CP-62,993), levofloxacin
- Where
- 75 sites in United States, Brazil and 11 more
- Volunteers
- 551 people
- Sponsor
- Pfizer
COVID-19
[14C] Study to Investigate the Mass Balance and Biotransformation of WPV01 in Healthy Adult Chinese Male Participants
This is a single-center, non-randomized, open-label, single-dose, Phase I clinical study to evaluate the mass balance and biotransformation, safety and tolerability of WPV01 in healthy adult chinese male participants following a…
- Trial name
- NCT07080658
- Testing
- [14C]-WPV01
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
Influenza
Study of the Safety and Immunogenicity of NasoVAX Extension
This study is an extension to Study ALT-103-201, a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of NasoVAX in healthy adults 18 to 49 years of age.
- Trial name
- NCT03760549
- Testing
- Subjects were administered NasoVAX high dose
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
SARS-CoV-2 Infection
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
The primary objectives of this open-label trial were to evaluate the safety and pharmacokinetics (PK) of Anti-SARS-CoV-2 Immunoglobulin (Human) Investigational Product (COVID-HIG) administered intramuscularly (IM), subcutaneously…
- Trial name
- NCT05142306
- Testing
- COVID-HIG
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection
A Study to Learn About the Study Medicine Zavicefta After it is Released Into the Markets in Korea
The purpose of this study is to learn about the safety and effectiveness of Zavicefta once released into the markets in Korea. This study is to learn about Zavicefta in patients with difficult types of infections in the abdomen…
- Conditions
- Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection, Hospital-acquired Pneumonia
- Trial name
- NCT05733104
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Pfizer
Covid-19
Exploratory Study to Evaluate the Efficacy of RUTI® Against SARS-COV-2 Infection (COVID-19) in Healthcare Workers
The aim of this study is to explore potential for reduction of incidence and/or morbidity of SARS-CoV-2 infection in healthcare personnel. The study will include a comparison between placebo and RUTI® vaccine in a 2:1 design.
- Trial name
- NCT04903184
- Testing
- RUTI® vaccine
- Where
- 6 sites in Argentina
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- RUTI Immunotherapeutics S.L.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.